Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fed Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

NCT04865536
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Lutein and the Retinopathy of Prematurity

NCT00672230
View directory record Official record
Conditions
Lactation
Interventions
Lutein supplement
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older · Female only
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Results available

The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants

NCT00167388
View directory record Official record
Conditions
Anemia of Prematurity
Interventions
feed during blood transfusion
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Weeks to 38 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 18 Fed, Healthy Adult Subjects

NCT00932880
View directory record Official record
Conditions
Healthy
Interventions
Amlodipine Besylate, Norvasc
Drug
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
18 Years to 45 Years
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2009 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects

NCT02013388
View directory record Official record
Conditions
Healthy
Interventions
N91115, Placebo, Placebo-Day 1 only
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions

NCT00829790
View directory record Official record
Conditions
Healthy
Interventions
Doxycycline Monohydrate
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Healthy Participants

NCT03929744
View directory record Official record
Conditions
Healthy
Interventions
LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

NCT03492697
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06882961 Immediate Release Tablet, PF-06882961 Controlled Release Tablet (long), PF-06882961 Controlled Release Tablet (short), PF-06882961 Immediate Release Solution
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

NCT01015040
View directory record Official record
Conditions
Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions
solifenacin succinate suspension, solifenacin succinate tablet
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Food Effect of K-877 in Healthy Adult Volunteers

NCT04742218
View directory record Official record
Conditions
Healthy
Interventions
K-877
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bovine Milk Oligosaccharide Study

NCT01814540
View directory record Official record
Conditions
Healthy
Interventions
Bovine Milk Oligosaccharide, Placebo Glucose Polymer
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects

NCT01068730
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
metformin (Diabex), metformin (Glucophage™)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

NCT03155893
View directory record Official record
Conditions
Healthy
Interventions
ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition

NCT01888328
View directory record Official record
Conditions
Healthy
Interventions
Isotretinoin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Quadrangle Drive, Chapel Hill,, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants

NCT07361367
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects

NCT01142063
View directory record Official record
Conditions
Healthy
Interventions
Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Zelquistinel in Fasted or Fed State

NCT07099989
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Zelquistinel 3 mg, Zelquistinel 10 mg
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food

NCT02482935
View directory record Official record
Conditions
Healthy
Interventions
Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Mineral Absorption in Infants Fed Infant Formula

NCT01177917
View directory record Official record
Conditions
Mineral Absorption in the Urine
Interventions
Infant Formula
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
56 Days to 70 Days
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
5
States / cities
Coralville, Iowa • Louisville, Kentucky • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

NCT01975220
View directory record Official record
Conditions
Healthy
Interventions
Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir

NCT02961660
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Odalasvir
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

NCT02851797
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
givinostat, placebo
Drug
Lead sponsor
Italfarmaco
Industry
Eligibility
6 Years to 17 Years · Male only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Davis, California • San Diego, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 17, 2026, 5:14 AM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

NCT03359733
View directory record Official record
Conditions
Lymphoma, Malignant, Advanced Solid Neoplasms
Interventions
TAK-659
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • Detroit, Michigan • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 17, 2026, 5:14 AM EDT